ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 248.4 USD | -3.44% |
|
-2.40% | -12.86% |
| 05-31 | ROCHE HOLDINGS AG : Gets a Neutral rating from UBS | ZD |
| 05-31 | Transcript : Roche Holding AG - Shareholder/Analyst Call |
| Sales 2024 * | 60.36B 66.86B 5,252B | Sales 2025 * | 63.82B 70.69B 5,552B | Capitalization | 186B 207B 16,224B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.27B 14.7B 1,154B | Net income 2025 * | 14.76B 16.35B 1,284B | EV / Sales 2024 * | 3.32 x |
| Net Debt 2024 * | 13.79B 15.27B 1,200B | Net Debt 2025 * | 7.91B 8.76B 688B | EV / Sales 2025 * | 3.05 x |
| P/E ratio 2024 * |
13.6
x | P/E ratio 2025 * |
12.3
x | Employees | 103,605 |
| Yield 2024 * |
4.24% | Yield 2025 * |
4.36% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
| 1 day | -3.44% | ||
| 1 week | -2.40% | ||
| 1 month | +4.00% | ||
| 3 months | -4.66% | ||
| 6 months | -6.28% | ||
| Current year | -12.86% |
1 week
247.20
257.20
1 month
233.12270.00
Current year
233.12300.00
1 year
233.12323.78
3 years
233.12430.00
5 years
233.12430.00
10 years
209.55430.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 31/12/02 | |
Severin Schwan
CHM | Chairman | 57 | 31/12/07 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 31/03/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 02/03/15 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 31/12/95 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 248.4 | -3.44% | 2,062 |
| 30/05/24 | 257.2 | +2.10% | 322 |
| 29/05/24 | 251.9 | +0.16% | 1,083 |
| 28/05/24 | 251.5 | -1.15% | 16,092 |
| 24/05/24 | 254.5 | +0.34% | 232 |
Delayed Quote OTC Markets, May 31, 2024 at 08:20 pm
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
05/06/2024
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231
CHF
Average target price
277.5
CHF
Spread / Average Target
+20.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +6.17% | 164B | |
| -0.45% | 162B | |
| -.--% | 122B |
- Stock Market
- Equities
- ROG Stock
- RHHVF Stock
